Cited by 780HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Open access

Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler Jr, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, Solit, David B.·2018·Nature

DOI 10.1038/nature25475PMC PMC5808581

Open this paper in CoChat — free account

Abstract

Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature25475

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777

Show all 54 references

Sorted by citations

Items 501–600 of 779

Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma
Fang, X., Mou, H., Ying, X., Hou, X., Wang, L., Wu, Y., Yan, N., Guo, L., & Liao, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1024677 · Cited by 6
Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report
Xu, J., He, B., Wang, Y., Wu, M., Lu, Y., Su, Z., Liu, S., Yin, F., Zhou, J., & Hu, W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1268260 · Cited by 6
Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations
Manrai, P. A., McHenry, A. J., Sun, T., Santin, A. D., Ratner, E., Lin, D. I., Elvin, J. A., Hui, P., & Buza, N. (2024) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000001050 · Cited by 6
Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations
Jongen, L., Floris, G., Boeckx, B., Smeets, D., Lambrechts, D., Borght, S. V., Laenen, A., Mann, G., Cutler, R. E., Lalani, A. S., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5049-7 · Cited by 6
Self-citation
Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non–small-cell Lung Cancer
Al-Obeidi, E., Li, T., & Kelly, K. L. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.09.006 · Cited by 6
Progress and challenges in gastroesophageal cancer
Serra, O., Smyth, E. C., & Lordick, F. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100590 · Cited by 6
Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care
Mortimer, J. E., Kruper, L. L., Cianfrocca, M. E., Lavasani, S. M., Liu, S., Patel, N. H., Sedrak, M. S., Smith, W., Stewart, D. B., Waisman, J. R., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061984 · Cited by 6
An appraisal of emerging second line therapies for metastatic colorectal cancer
Smolenschi, C., Perret, A., Dall'Armellina, F., Boige, V., Malka, D., Hollebecque, A., & Ducreux, M. P. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1840975 · Cited by 6
Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials
Palmer, A. C., Plana, D., & Sorger, P. K. (2020) · Cell Systems · doi:10.1016/j.cels.2020.09.003 · Cited by 6
The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer
Orlov-Slavu, M. C., Popa, A. M., Tulin, A. D., Stoian, A. P., Poiană, C., Paleru, C., Calu, V., & Niţipir, C. (2021) · Cureus · doi:10.7759/cureus.16919 · Cited by 6
Generation and Integrated Analysis of Advanced Patient‐Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer
Devis, L., Vidal, A., Plata‐Peña, L., Santacana, M., García‐Mulero, S., Bonifaci, N., Noguera‐Delgado, E., Ruíz, N., Gil, M., Dorca, E., et al. (2022) · Advanced Science · doi:10.1002/advs.202204211 · Cited by 6
Human Epidermal Growth Factor Receptor 2–Mutant Non–Small-Cell Lung Cancer: Continued Progress But Challenges Remain
Cooper, A. J., & Gainor, J. F. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02550 · Cited by 7
Genomic profiling unlocks new treatment opportunities for ampullary carcinoma
Fabregat-Franco, C., Castet, F., Castillo, G., Salcedo, M., Sierra, A., López-Valbuena, D., Pando, E., Tian, T. V., & Macarulla, T. M. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104480 · Cited by 6
Beyond borders: engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer
Moorthy, T., Yalamandala, B. N., Huynh, T. M. H., Lien, H., Pan, W.-C., Iao, H. M., Chang, Y., & Hu, S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01935-4 · Cited by 5
Melatonin combined with antineoplastic drugs or natural products for cancer treatment: An update
Trejo‐Solís, C., Rojas‐Tomé, I. S., Jung-Cook, H. H., & Palomares‐Alonso, F. (2025) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2025.100239 · Cited by 5
Basket Trials: Past, Present, and Future
Murciano‐Goroff, Y. R., Uppal, M., Chen, M. F., Harada, G., & Schram, A. M. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-012927 · Cited by 6
Self-citation
Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma
Pezzicoli, G., Ciciriello, F., Musci, V., Minei, S., Biasi, A., Ragno, A., Cafforio, P., & Rizzo, M. (2024) · Medicina · doi:10.3390/medicina60040585 · Cited by 5
Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation
Chung, C., & Umoru, G. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241242684 · Cited by 5
Clinical Impact of Somatic Genomic Testing on Breast Cancer Care
Khalid, T., Cutress, R., Remer, M., & Copson, E. (2024) · Clinical Oncology · doi:10.1016/j.clon.2024.10.037 · Cited by 5
The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways
Yayli, G., Tokofsky, A., & Nayar, U. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1461190 · Cited by 5
Genomic landscape of breast cancer in elderly patients
Selenica, P., Dopeso, H., Repetto, M., Basili, T., Gazzo, A. M., Schwartz, C. J., Derakhshan, F. N., Marra, A., Ferrando, L., Beets‐Tan, R. G. H., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00781-4 · Cited by 6
A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
Ma, J., Li, X., Zhang, Q., Li, N., Sun, S., Zhao, S., Zhao, Z., & Li, M. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101444 · Cited by 5
Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research
Cardillo, A. B., Kovar, S., Roper, N., Hicks, D. G., & Velez, M. J. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000719 · Cited by 5
Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
Mu, Y., Meng, Y., Du, Y., Liu, X., & Zhang, J. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15130 · Cited by 5
Heterogeneous ERBB gene pathways, their targeted treatment and possible molecular mechanisms of resistance in metastatic gallbladder cancer
Patel, A. K., Sarin, A., Marimuthu, R., Madarapu, C. S., Pandit, A., Shelly, D., Sharanya, J., Veldore, V. H., Suresh, P., & Tilak, T. (2024) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2024.01.006 · Cited by 5
Molecular Pathology of Urothelial Carcinoma
Al‐Ahmadie, H. A., & Netto, G. J. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.08.010 · Cited by 5
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial
Goldman, J. W., Bueno, A. M., Dooms, C., Jhaveri, K. L., de Miguel, M., Piha-Paul, S. A., Unni, N. G., Zick, A., Mahipal, A., Suga, J. M., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.12.003 · Cited by 5
Self-citation
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations
Piha-Paul, S. A., Tseng, C., Tran, H. T., Naing, A., Dumbrava, E. E. I., Karp, D., Rodon, J. A., Yap, T. A., Raghav, K. P. S., Damodaran, S., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104136 · Cited by 5
Self-citation
Time to tackle the blood‐brain barrier in HER2‐mutant lung cancer
Lin, J. J., & Gainor, J. F. (2019) · Cancer · doi:10.1002/cncr.32460 · Cited by 5
Mutant HER2 needs mutant HER3 to be an effective oncogene
Trenker, R., Diwanji, D. C., & Jura, N. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100361 · Cited by 5
Update on HER2 expression in breast cancer
Krystel‐Whittemore, M., & Wen, H. Y. (2022) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2022.01.001 · Cited by 5
Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors
Wang, J., Zhang, B., Cheng, X., Li, Q., Lv, H., Nie, C., Chen, B., Xu, W., Zhao, J., He, Y., et al. (2022) · Journal of Oncology · doi:10.1155/2022/4233782 · Cited by 6
HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function
Mitani, Y., Ohashi, S., Kikuchi, O., Nakai, Y., Ida, T., Mizumoto, A., Yamamoto, Y., Saito, T., Kataoka, S., Matsubara, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13189-y · Cited by 5
Breast Cancer Pathology in the Era of Genomics
Wen, H. Y., & Collins, L. C. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.08.004 · Cited by 6
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019
Lau, D. K., Burge, M., Roy, A. C., Chau, I., Haller, D. G., Shapiro, J. D., Peeters, M., Pavlakis, N., Karapetis, C. S., Tebbutt, N. C., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744439 · Cited by 5
Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need
Montazeri, K., & Sonpavde, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1855981 · Cited by 5
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Koivu, M. K. A., Chakroborty, D., Tamirat, M. Z., Johnson, M. S., Kurppa, K. J., & Elenius, K. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0590 · Cited by 5
HER2 alterations in non-small-cell lung cancer – Druggable or undruggable?
Bondili, S. K., Nandhana, R., Noronha, V., Pawar, S., Menon, N. S., Shetty, O. A., Chougule, A., Mahajan, A., Kumar, R., Patil, V. M., et al. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_81_21 · Cited by 5
Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using 18F-FDG PET/CT Dual-Phase Imaging
Zhang, J., Liu, Y., Fan, H., Wang, W., Shao, W., Cao, G., & Shi, X. (2023) · Academic Radiology · doi:10.1016/j.acra.2022.12.036 · Cited by 5
Emerging Targeted Therapies for HER2-Mutant NSCLC
Rio, B. D., Masini, S., Cáceres-Galvis, C., Torres-Jiménez, J., Bote, H., Berjaga, M. Z., Baena-, J., Serrano, C., Nuñez, J. A., Ponce-Aix, S., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103899 · Cited by 4
Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives
Testi, I., Giudice, G. C., Salfi, G., Pedrani, M., Merler, S., Turco, F., Tortola, L., & Vogl, U. M. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00279 · Cited by 4
Ubiquitin-Activating Enzyme E1 (UBA1) as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Insights into Immune Infiltration and Functional Implications
Feng, M., Cui, H., Li, S., Li, L., Zhou, C., Chen, L., Cao, Y., Gao, Y., & Li, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312696 · Cited by 4
Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study
Dong, Y., Yang, G., Yang, Y., Zhang, S., Wang, Y., & Xu, H. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108062 · Cited by 4
Mutational Profile of Blood and Tumor Tissue and Biomarkers of Response to PD-1 Inhibitors in Patients with Cutaneous Squamous Cell Carcinoma
Chang, M. J., Stamos, D. B., Urtis, C., Bowers, N. L., Schmalz, L., Deyo, L. J., Porebski, M. F., Jabir, A. R., Bunch, P. M., Lycan, T. W., et al. (2025) · Cancers · doi:10.3390/cancers17071172 · Cited by 4
Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
Chow, C. Y. C., Lie, E. F., Wu, C., & Chow, L. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.964824 · Cited by 4
HER2 status based on breast cancer guidelines as a useful prognostic marker of T2 gallbladder cancer
Kwon, C. H., Seo, H. I., Kim, D. U., Han, S. Y., Kim, S., Lee, S. J., & Jeon, D. Y. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.10.020 · Cited by 4
Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
Radford, M., Abushukair, H. M., Hentzen, S., Cavalcante, L. L., & Saeed, A. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-36 · Cited by 5
A frequentist design for basket trials using adaptive lasso
Kanapka, L. G., & Ivanova, A. (2023) · Statistics in Medicine · doi:10.1002/sim.9947 · Cited by 4
Genomics in Clinical trials for Breast Cancer
Enoma, D. (2023) · Briefings in Functional Genomics · doi:10.1093/bfgp/elad054 · Cited by 4
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2024) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2023.11.01 · Cited by 5
Dacomitinib exhibits promising activity against the rare HER2 exon 20 insertion M774delinsWLV in lung cancer: A case report and literature review
Yang, G., Liu, R., & Tang, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30312 · Cited by 4
Agnostic drug development revisited
Hernando‐Calvo, A., Rossi, A., Vieito, M., Voest, E. E., & Garralda, E. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102747 · Cited by 4
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma
Abou‐Alfa, G. K., Meyer, T., Gian, R. K., Piha-Paul, S. A., Light, J. S., Sherrin, S., Yaqubie, A., O’Neill, A. C., Harding, J. J., Al-Rajabi, R. M. T., et al. (2024) · Liver Cancer · doi:10.1159/000540290 · Cited by 4
Self-citation
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer
Pastò, B., Vida, R., Dri, A., Foffano, L., Rossa, S. D., Gerratana, L., & Puglisi, F. (2024) · The Breast · doi:10.1016/j.breast.2024.103859 · Cited by 4
The Role of HER2 in Cancer and Its Influence on the Tumor Microenvironment
Choi, S., Kim, M., & Kim, M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009458 · Cited by 4
Catalyzing the field of precision oncology, one basket at a time
Pao, W. J., & Fodor, I. K. (2018) · Nature Medicine · doi:10.1038/nm.4530 · Cited by 4
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)
Kim, J., Lee, E., Park, K., Im, S., Sohn, J., Lee, K. S., Chae, Y. S., Kim, J. H., Kim, T.-Y., Jung, K. H., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05400-y · Cited by 4
The Use of Epidermal Growth Factor Receptor Type 2-Targeting Tyrosine Kinase Inhibitors in the Management of Epidermal Growth Factor Receptor Type 2-Positive Gastric Cancer: A Narrative Review
AlMazmomy, A. M., Al-Hayani, M. M., Alomari, M. A., & Bazi, A. (2019) · Cureus · doi:10.7759/cureus.6295 · Cited by 4
Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers
Casolino, R., Amato, F., Rae, C. J., Puttagunta, S. A., Braconi, C., Nash, T., MacLeod, M., Sanchon-Sanchez, P., Roxburgh, P., EVANS, J., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.012 · Cited by 4
HKI-272 contributes to gemcitabine-mediated anti-proliferative and anti-metastatic effects through EGFR suppression in gallbladder cancer
Yang, X., Chen, T., Hu, J. H., Wang, J., & Yang, D. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.10.004 · Cited by 4
Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2–overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study
Lavingia, V. K., Thummar, V., & Mehta, P. (2022) · SAGE Open Medical Case Reports · doi:10.1177/2050313x221137447 · Cited by 4
Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients
Shang, Y., Mo, J., Huo, R., Li, X., Fang, G., Wei, Z., Gu, G., Zhu, X., Zhang, C., Liu, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1064598 · Cited by 4
Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
Mauri, G., Gori, V., Patelli, G., Roazzi, L., Rizzetto, F., Carlis, L. G. D., Mariani, A., Cavallari, U., Prada, E., Cipani, T., et al. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-02976-0 · Cited by 4
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review
Metro, G., Baglivo, S., Moretti, R., Bellezza, G., Sidoni, A., & Roila, F. (2020) · Oncology and Therapy · doi:10.1007/s40487-020-00121-5 · Cited by 4
Varianteninterpretation in der molekularen Pathologie und Onkologie
Horak, P., Leichsenring, J., Kreutzfeldt, S., Kazdal, D., Teleanu, V., Endris, V., Volckmar, A., Renner, M., Kirchner, M., Heilig, C. E., et al. (2021) · Der Pathologe · doi:10.1007/s00292-021-00938-5 · Cited by 4
Many mutations in one clinical-trial basket
Mardis, E. R. (2018) · Nature · doi:10.1038/d41586-018-01312-x · Cited by 4
Next generation sequencing and anti-cancer therapy
Sohn, J. (2019) · Journal of Korean Medical Association · doi:10.5124/jkma.2019.62.2.119 · Cited by 4
Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant
Gao, Z., Xu, J., Wang, Y., Wu, J., & Sun, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.715554 · Cited by 4
Prevalence of HER2 overexpression and amplification in uterine cervical cancer: a systematic review and a meta-analysis.Preprint
Itkin, B., García, A. A., Straminsky, S., Adelchanow, E. D., Pereyra, M. G., Haab, G. A., & Bardach, A. (2021) · Research Square · doi:10.21203/rs.3.rs-288200/v1 · Cited by 4
The role of HER2-targeted therapy in urothelial carcinomas
Aragon‐Ching, J. B., & Galsky, M. D. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2517581 · Cited by 4
Copper‐Catalyzed Carboamination of Unactivated Alkenes to Synthesize β‐Lactams with Trichloroacetonitrile
Wang, X., Cui, J., & Zeng, R. (2024) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4928 · Cited by 3
Endometrial carcinomas – Challenges and updates on selected topics
Buza, N., Sun, T., & Hui, P. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.106016 · Cited by 3
HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape
Muscolino, P., Fassi, E., Signorelli, D., Colonese, F., Cortinovis, D. L., Russo, G. L., Pasello, G., Infurna, C., Ciappina, G., Berretta, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052334 · Cited by 3
Overcoming Trastuzumab–Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer
Yamamoto, Y. (2026) · Cancers · doi:10.3390/cancers18060932 · Cited by 3
Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugates
Wafa, H., van Creij, N. C. H., Guenther, M., Noeparast, M., Subiela, J. D., Terbuch, A., Niedersuess‐Beke, D., Čulig, Z., Ormanns, S., & Pichler, R. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103173 · Cited by 3
Inhibition of mutationally activated HER2
Collins, S. J., Guo, J., Rizzo, R. C., & Miller, W. T. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14125 · Cited by 3
Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer
Romero-Pérez, I., Dı́az-Rodrı́guez, E., Sánchez-Díaz, L., Montero, J. C., & Pandiella, A. (2024) · Oncogenesis · doi:10.1038/s41389-024-00531-4 · Cited by 3
Breast cancer genomic analyses reveal genes, mutations, and signaling networks
Manjunath, G. K., Sharma, S., Nashier, D., Vasanthaiah, S., Jha, S., Bage, S., Mitra, T., Goyal, P., Neerathilingam, M., & Kumar, A. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01484-y · Cited by 3
Molecular Classification of Urothelial Carcinoma
Chen, J., & Al‐Ahmadie, H. A. (2024) · Surgical pathology clinics · doi:10.1016/j.path.2024.09.003 · Cited by 3
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
Abadi, K. R. N., Dupain, C., Guillou, I., Sanchez, R., Nedara, K., Marret, G., Hescot, S., Sablin, M.-P., Ajgal, Z. C., Neuzillet, C., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100092 · Cited by 3
Successful Treatment of HER2 V659E Mutation‐Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report
Nishihara, M., Shinno, Y., Masui, Y., Masuda, K., Matsumoto, Y., Okuma, Y., Yoshida, T., Goto, Y., Horinouchi, H., Yamamoto, N., et al. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70100 · Cited by 3
The Role of HER2 Testing in Advanced Colorectal Cancer
Mehta, R. J. (2018) · Current Colorectal Cancer Reports · doi:10.1007/s11888-018-0417-6 · Cited by 3
Computational-aided rational mutation design of pertuzumab to overcome active HER2 mutation S310F through antibody–drug conjugates
Bai, X., Xu, L., Wang, Z., Zhuang, X., Ning, J., Sun, Y., Wang, H., Guo, Y., Xu, Y., Guo, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413686122 · Cited by 5
Clinical implications of breast cancer tumor genomic testing
Damodaran, S., Sember, Q., & Arun, B. (2020) · The Breast Journal · doi:10.1111/tbj.13966 · Cited by 3
Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review
Qu, Y., Liu, Y., Ding, K., Li, Y., Hong, X., & Zhang, H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s289876 · Cited by 3
Prädiktive Mutationsdiagnostik bei Mammakarzinomen
Kreipe, H. H., & Sinn, H. (2021) · Der Pathologe · doi:10.1007/s00292-021-00929-6 · Cited by 3
Natural History and Characteristics of ERBB2 -mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE
Lenoue-Newton, M. L., Chen, S., Stricker, T., Hyman, D. M., Blauvelt, N., Bedard, P. L., Meric‐Bernstam, F., Punglia, R. S., Schrag, D., Lepisto, E. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0885 · Cited by 3
Self-citation
Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report
Li, S., Liu, Q., Liu, M., & Liu, T. (2022) · Cancer Management and Research · doi:10.2147/cmar.s365951 · Cited by 3
Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and OrganoidsPreprint
Li, S., Primeau, T. M., Highkin, M. K., Pratt, S. L., Tipton, A. R., Vemalapally, N., Monsey, J. D., Tao, Y., Luo, J. R., Hagemann, I. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.19.572069 · Cited by 3
Self-citation
ERBB2-Mutant Gastrointestinal Tumors Represent Heterogeneous Molecular Biology, Particularly in Microsatellite Instability, Tumor Mutation Burden, and Co-Mutated Genes: An In Silico Study
Uchida, S., & Sugino, T. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45090468 · Cited by 2
A narrative review of advances in the management of urothelial cancer: Diagnostics and treatments.
Wu, S., Xiong, S., Li, J., Hong, G., Xie, Y., Tang, Q., Hao, H., Sheng, X., Li, X., & Lin, T. (2024) · PubMed Central · doi:10.14440/bladder.2024.0003 · Cited by 2
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers
Heeke, A. L., Elliott, A., O'Keefe, K., Livasy, C., Symanowski, J. T., Steiner, M. R., Kang, I. M., Hoon, D. S. �., Walker, P., Sledge, G. W., et al. (2025) · JCO Precision Oncology · doi:10.1200/po.23.00719 · Cited by 4
Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls
Russo, G., Scimone, C., Palumbo, L., Roscigno, G., Sarracino, C., Tomaiuolo, I., Pisapia, P., Pepe, F., Rocco, D., Gridelli, C., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104748 · Cited by 2
Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations
Shimauchi, A., Iwama, E., Ibusuki, R., Tsutsumi, H., Shibahara, D., Otsubo, K., Yoneshima, Y., Tanaka, K., & Okamoto, I. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03126-x · Cited by 2
Anti-HER2 treatment in solid tumors beyond breast cancer with HER2 overexpression — an exciting new remake of the old target
Semeradt, J., Krawczyk, O., Krawczyk, N., Jędrzejczak, P., Kopyciński, W., & Dębska-Szmich, S. (2025) · Oncology in Clinical Practice · doi:10.5603/ocp.106480 · Cited by 2
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors
Egebjerg, K., Spanggaard, I., Ahlborn, L. B., Rohrberg, K. S., Harsløf, L. B. S., Hoejgaard, M., Schmidt, A. Y., Lassen, U., Tuxen, I. V., Hasselby, J. P., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14599-7 · Cited by 2
Personalized medicine in oncology: advancements, difficulties, and prospects
Bansal, D. (2025) · International Journal of Therapeutic Innovation. · doi:10.55522/ijti.v3i4.0121 · Cited by 2
Toxicity Profile of New Therapies in Metastatic Urothelial Carcinoma and Its Impact on Treatment Selection
Guerrero, P., González-Merino, C., de Quevedo, C. G., Subiela, J. D., Sotoca, P., Calvo, J. C., Bueno, C., García, A., Orejana, I., MEDINA, A. A., et al. (2025) · Cancers · doi:10.3390/cancers17213523 · Cited by 2
Tumor-normal sequencing reveals novel TP53 germline and clinically actionable somatic mutations in Nigerian breast cancer patients
Onyia, A. F., Lawal, A. O., Ogo, C. N., Nkom, E. S., Lasebikan, N. N., Ayegbusi, O. T., Campos, O. C. D., Rotimi, O. A., Oyelade, J. O., Aliyu, U. M., et al. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.11.012 · Cited by 2
Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies
Ojala, V. K., Ahonen, S., Peltola, S., Tuohisto-Kokko, A., Esparta, O., Suominen, P., Jokilammi, A., Farahani, I. K., Chakroborty, D., Dibus, N., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70189 · Cited by 2
Self-citation

Authors: Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J., Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler Jr, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J., & Solit, D. B.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
The University of Texas MD Anderson Cancer Center (US)
Vall d'Hebron Hospital Universitari (ES)
Dana-Farber Cancer Institute (US)
USC Norris Comprehensive Cancer Center (US)
Vanderbilt University (US)
Peter MacCallum Cancer Centre (AU)
Washington University in St. Louis (US)
Puma Biotechnology (United States) (US)
Corresponding author: Hyman, David M.
ORCID: Hyman, David M.
Piha-Paul, Sarina A.
Won, Helen
Rodon, Jordi
Saura, Cristina
Shapiro, Geoffrey I.
Juric, Dejan
Quinn, David I.
Mayer, Ingrid A.
Boni, Valentina
Calvo, Emiliano
Loi, Sherene
Lockhart, Albert C.
Erinjeri, Joseph P.
Scaltriti, Maurizio
Ulaner, Gary A.
Patel, Juber
Bouvier, Nancy
Murali, Rajmohan
Schram, Alison M.
Smyth, Lillian M.
Jhaveri, Komal
Li, Bob T.
Drilon, Alexander
Harding, James J.
Iyer, Gopa
Taylor, Barry S.
Berger, Michael F.
Xu, Feng
Eli, Lisa D.
Lalani, Alshad S.
Bryce, Richard P.
Arteaga, Carlos L.
Solit, David B.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2018-01-31
Volume: 554
Issue: 7691
Pages: 189-194
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature25475
PMC: PMC5808581
OpenAlex: W2785610956
Cited by: 780
References: 54
Citations by year: 2026: 40 · 2025: 64 · 2024: 89 · 2023: 99 · 2022: 113 · 2021: 103 · 2020: 113 · 2019: 86 · 2018: 69
FWCI: 34.53
Type: journal article
Language: en
Update notices: correction (2019-02-12)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Minerva Access (University of Melbourne) (submittedVersion)
Funders: Puma Biotechnology
National Institutes of Health (UL1TR000371)
National Cancer Institute (R01CA204749, U01CA180964, R01CA080195, P50CA098131, P30CA008748, P30CA016672, T32CA009207, R25CA020449, P30CA014089)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, ERBB2, HER3, neratinib, basket trials, breast cancer, biliary tract cancer, cervical cancer, targeted therapy
MeSH terms: Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Quinolines, Cohort Studies, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Mutation, Missense, Receptor, ErbB-3, Protein Kinase Inhibitors, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks